Fishman Mark 4
4 · Beam Therapeutics Inc. · Filed Feb 11, 2020
Insider Transaction Report
Form 4
Fishman Mark
Director
Transactions
- Conversion
Common Stock
2020-02-10+17,007→ 17,007 total - Conversion
Series A-1 Preferred Stock
2020-02-10−15,768→ 0 total→ Common Stock (15,768 underlying) - Conversion
Series A-2 Preferred Stock
2020-02-10−1,239→ 0 total→ Common Stock (1,239 underlying)
Footnotes (1)
- [F1]Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock.